
FDA approves Merck’s Enflonsia for RSV prevention
The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season. Enflonsia is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct,… Read More













